Abemaciclib in Patients with End-Stage Renal Disease and Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Report of 2 Cases

Abemaciclib in Patients with End-Stage Renal Disease and Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Report of 2 Cases

Cyclin4/6-dependent kinase inhibitors (CDKIs) plus hormonotherapy currently represent the standard golden treatment for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor-2-negative (her-2−) advanced breast carcinoma. Among CDKIs, abemaciclib is the most active. N...

Full description

Bibliographic Details
Main Author: Vittorio Gebbia
Format: Article
Language:English
Published: Karger Publishers 2022-03-01
Series:Case Reports in Oncology
Subjects:
metastatic breast cancer
estrogen receptor
abemaciclib
end-stage renal disease
Online Access:https://www.karger.com/Article/FullText/523856

Internet

https://www.karger.com/Article/FullText/523856

Similar Items